Amicus Therapeutics

$11.21 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Amicus Therapeutics

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Stock Analysis

last close $10.45
1-mo return -15.5%
3-mo return -10.1%
avg daily vol. 2.14M
52-week high 25.39
52-week low 8.6
market cap. $2.9B
forward pe -
annual div. -
roe -68.5%
ltg forecast -
dividend yield -
annual rev. $294M
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe